GRAIL (GRAL) is in focus after the U.S. FDA scheduled an advisory panel meeting on September 23, 2026 to review the Premarket Approval application for its Galleri multi-cancer early detection blood test.

The FDA advisory panel date comes after a busy period for GRAIL, with recent earnings and ongoing Galleri trial updates in focus. However, the stock’s short term share price returns remain weak while the 1 year total shareholder return of 125.62% signals powerful longer term momentum.

If the Galleri review has you thinking about where else AI driven healthcare tools might change the game, this is a good moment to scan 42 healthcare AI stocks

For GRAIL, the sharp 1 year rebound alongside weaker year to date returns raises a simple issue: Are investors now pricing the business on Galleri’s fundamentals or on changing sentiment ahead of that FDA panel, and what does the current valuation suggest?

Most Popular Narrative: 2.1% Undervalued

GRAIL's most followed narrative puts fair value at about $72.38, only slightly above the last close of $70.89. This keeps the focus on the assumptions behind that small gap.

Ongoing positive clinical trial results including substantially higher cancer detection and positive predictive value with consistent specificity for Galleri in population-scale studies are setting the stage for robust FDA approval and broad payer reimbursement, which could unlock significant new revenue streams and accelerate top-line growth.

Curious what sits behind that fair value for GRAIL. The narrative leans on rapid revenue growth, improving margins, and a premium future earnings multiple. The exact mix might surprise you.

Result: Fair Value of $72.38 (UNDERVALUED)

However, GRAIL's story still faces clear pressure points, including ongoing heavy losses and uncertain FDA and payer decisions that could rapidly change how investors view that 2.1% gap.

Another View on GRAIL’s Valuation

While the main GRAIL narrative points to a small 2.1% gap between the $70.89 share price and the $72.38 fair value, the simple sales multiple tells a different story. The current P/S of 19.2x is well above the US Biotechs average of 11.3x, the peer average of 7.3x, and the fair ratio of 7.1x. That leaves you weighing whether this premium signals upside potential or a lot of expectation already in the price.

To see how those sales multiples stack up in more detail, including how they compare against peers and that fair ratio the market could move toward, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals around GRAIL, including both risks and rewards, it makes sense to move fast and check the full picture for yourself. Start by weighing the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond GRAIL?

If GRAIL has sharpened your thinking, do not stop here. A broader watchlist of quality ideas can help you react faster when prices move.

• Spot potential value opportunities early and scan 50 high quality undervalued stocks before other investors start paying attention.
• Prioritize resilience and capital protection and filter for companies in the 79 resilient stocks with low risk scores that fit your comfort with volatility.
• Hunt for lesser known opportunities with solid fundamentals by checking the screener containing 20 high quality undiscovered gems while they are still off most radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.